NEJM: Wegovy led to ≥10% BMI loss in almost 80% of children in STEP Young vs 0% with placebo
Nov 16, 2026, 10:20 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A strong pediatric efficacy readout expands Wegovy's addressable market and could increase long-term revenue if regulators approve pediatric labeling and payers reimburse; the economic impact depends on safety, regulatory decisions, and pricing/coverage.
AI summary
What happened, with direct paths to the underlying reporting
NEJM-published STEP Young data: Wegovy produced ≥10% BMI reduction in almost 80% of children (age 6–<12) versus 0% with placebo.
The New England Journal of Medicine published STEP Young trial results showing Wegovy produced a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, versus 0% with placebo.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Novo Nordisk posted a stronger-than-expected Q3, powered by Wegovy with revenue of 79.2 billion DKK (+4% YoY) and EBIT of 31.7 billion DKK, ahead of estimates. The company raised…
Novo's post-study analysis shows 25% average weight loss at 68 weeks in about 2,300 women, with menopause-stratified gains up to 26.7%. While confirmatory work is needed, the data…
Jiangsu Hengrui Pharmaceutical agreed to license global rights to HRS-1596 to Novo Nordisk for as much as $2.6 billion. The deal broadens NVO’s obesity-drug portfolio and signals…